| Generation of T cells from Human and Nonhuman Primate Pluripotent Stem Cells
|
|
Author:
Date:
2020-07-05
[Abstract] Pluripotent stem cells (PSCs) have the potential to provide homogeneous cell populations of T cells that can be grown at a clinical scale and genetically engineered to meet specific clinical needs. OP9-DLL4, a stromal line ectopically expressing the Notch ligand Delta-like 4 (DLL4) is used to support differentiation of PSCs to T-lymphocytes. This article outlines several protocols related to generation of T cells from human and non-human primate (NHP) PSCs, including initial hematopoietic differentiation of PSC on OP9 feeders or defined conditions, followed by coculture of the OP9-DLL4 cells with the PSC-derived hematopoietic progenitors (HPs), leading to efficient differentiation to T lymphocytes. In addition, we describe a protocol for robust T cell generation from hPSCs conditionally ...
[摘要] [摘要] 多能干细胞（PSCs）有潜力提供同质的T细胞群体，这些细胞可以在临床规模上生长，并通过基因工程来满足特定的临床需求。OP9-DLL4是一种异位表达Notch配体Delta-like 4（DLL4）的基质细胞系，用于支持psc向T淋巴细胞的分化。本文概述了从人类和非人类灵长类（NHP）PSC中产生T细胞的几种方法，包括在OP9喂食者或特定条件下对PSC进行初始造血分化，然后将OP9-DLL4细胞与PSC衍生的造血祖细胞（HPs）共培养，从而有效地分化成T淋巴细胞。此外，我们描述了一个从有条件表达ETS1的hPSCs中产生健壮T细胞的方案。所提出的协议提供了一个平台，用于疾病建模和评估其在大型动物模型免疫治疗中的应用。
[背景] T淋巴细胞（T细胞）在细胞介导的免疫反应中起着关键作用，参与肿瘤细胞的监测和杀伤。在过去的几十年里，已经开发了几种策略来重定向、培养和/或增强抗肿瘤的T淋巴细胞（Houot等人，2015年；June等人，2018年），并将其用于基于T细胞的过继免疫治疗。最近的临床试验表明，用嵌合抗原受体（CAR）-T细胞治疗复发性和难治性淋巴瘤患者的疗效显著（Riviere和Sadelain，2017）。
人类多能干细胞（hPSCs），包括胚胎（hESCs）和诱导（hiPSCs），为生产用于过继性细胞免疫疗法的T细胞提供了一种很有前景的资源，可与基因工程技术相结合，产生现成的CAR ...
|
|
|
| Efficient Production of Functional Human NKT Cells from Induced Pluripotent Stem Cells − Reprogramming of Human Vα24+iNKT Cells
|
|
Author:
Date:
2017-05-20
[Abstract] Antigen-specific T cell-derived induced pluripotent stem cells (iPSCs) have been shown to re-differentiate into functional T cells and thus provide a potential source of T cells that could be useful for cancer immunotherapy. Human Vα24+ invariant natural killer T (Vα24+iNKT) cells are subset of T cells that are characterized by the expression of an invariant Vα24-Jα18 paired with Vβ11, that recognize glycolipids, such as α-galactosylceramide (α-GalCer), presented by the MHC class I-like molecule CD1d. Vα24+iNKT cells capable of producing IFN-γ are reported to augment anti-tumor responses, which affects both NK cells and CD8+ cytotoxic T lymphocytes to eliminate MHC- and MHC+ tumor cells, respectively. Here we describe a ...
[摘要] 抗原特异性T细胞来源的诱导多能干细胞（iPSCs）已显示重新分化为功能性T细胞，从而提供可用于癌症免疫治疗的T细胞的潜在来源。不变性自然杀伤T（Vα24 + iNKT）细胞的人Vα24 + 细胞是T细胞的子集，其特征在于与Vβ11配对的不变Vα24-Jα18的表达，其识别糖脂，如α-半乳糖神经酰胺（α-GalCer），由MHC I类分子CD1d呈递。据报道能够产生IFN-γ的Vα24 + i / KT细胞增加抗肿瘤反应，其影响NK细胞和CD8 +细胞毒性T淋巴细胞以消除MHC - 和MHC + 肿瘤细胞。在这里，我们描述了将人Vα24 + iNKT细胞重编程到iPSC中的鲁棒方案，然后将其重新分化为Vα24 + iNKT细胞（iPS-Vα24功能的iNKT）。我们进一步提供了测定iPS-Vα24 + iNKT细胞活性的方案。背景 以前有报道说，针对晚期非小细胞肺癌（NSCLC）和头颈部癌症的Vα24 + iNKT细胞癌免疫治疗的临床试验显示疗效，耐受性良好（Motohashi et al。等人，2009; Yamasaki等人，2011）。然而，已知来自外周血单核细胞（PBMC）的Vα24 ...
|
|
|
| iPS Cell Induction from Human Non-T, B cells from Peripheral Blood
|
|
Author:
Date:
2013-09-20
[Abstract] The generation of iPS cells gives an opportunity to use patient-specific somatic cells which are a valuable source for disease modeling and drug discovery. To promote these studies, it is important to make iPS cells from easily accessible and less invasive tissues like blood. Here, we describe the basic method to generate human iPS cells from adult peripheral blood. After the isolation of mononuclear cells, a combination of cytokines stimulates the expansion of hematopoietic stem/progenitor population, which is the main target of this protocol. The cells are transduced with plasmid mixture encoding reprogramming factors. In most cases, the plasmids are lost during the establishment of iPS clones.
[摘要] iPS细胞的产生提供了使用患者特异性体细胞的机会，其是用于疾病建模和药物发现的有价值的来源。 为了促进这些研究，重要的是使iPS细胞从容易获得和侵入性较小的组织如血液。 在这里，我们描述从成人外周血生成人类iPS细胞的基本方法。 在分离单核细胞后，细胞因子的组合刺激造血干/祖细胞群的扩增，这是该方案的主要目标。 用编码重编程因子的质粒混合物转导细胞。 在大多数情况下，质粒在iPS克隆的建立期间丢失。
|
|
|